NCT02736240View on ClinicalTrials.gov

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

PHASE3CompletedINTERVENTIONAL

Enrollment

2,760

Participants

Timeline

Start Date

April 8, 2016

Primary Completion Date

December 3, 2017

Study Completion Date

December 3, 2017

Conditions

Diseases Caused by Streptococcus Pneumoniae Serotypes

Interventions

BIOLOGICAL

7-valent pneumococcal conjugate vaccine

BIOLOGICAL

13-valent pneumococcal polysaccharide conjugate vaccine

All Listed Sponsors

lead

Walvax Biotechnology Co., Ltd.

INDUSTRY

NCT02736240 - Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old) | Biotech Hunter | Biotech Hunter